Mirza Mansoor Raza, Director, subtracted 2,056 shares of Karyopharm Therapeutics Inc. (KPTI) from its portfolio at the rate of $20.00 per share valuing $41,120 on Jan 09. The insider left behind 0 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $18.35, with a 2nd Resistance Point sitting at $19.47. Meanwhile, this company’s stock has a 1st Support Level at $16.61 and a 2nd Support Level at $15.99. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Karyopharm Therapeutics Inc. (KPTI) was $17.24. Karyopharm Therapeutics Inc. (KPTI) stock has lost -$1.23, or -6.66%, in the past five days. In the last full month, these shares have gained $0.49, or 2.93%. In the past three months, this stock’s price has risen by $7.04, or 69.02%. This year-to-date, Karyopharm Therapeutics Inc. (KPTI) shares have lost -$1.93, or -10.07%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Karyopharm Therapeutics Inc. (KPTI) stock, 50% of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Buy .”
With 62,790 K shares outstanding, this company currently has a market capitalization of $1,153,766K. Karyopharm Therapeutics Inc. (KPTI) generates $30,340 K in annual sales, amounting to annual net income of -$178,410 K. This stock has generated a 1-Year Total Return of 70.86%, a 3-Year Total Return of 81.57%, and a 5-year Total Return of -31.05%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Karyopharm Therapeutics Inc. (KPTI) reported earnings of -$0.67 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.84 per share, representing a 0.17 difference and 20.24% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.71 represented a 0.26 difference from the consensus estimate calling for -$0.97 per share, which was a 26.80% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.67 per share. This estimate came from a total of 6 Wall Street Analysts. Of those market experts, the high estimate was -$0.61 and the low estimate was -$0.74. In the year-ago quarter, Karyopharm Therapeutics Inc. (KPTI) generated per-share earnings of -$0.96. If the analysts are correct about the current quarter’s earnings, the growth will be +30.21%.
Turning our focus now to insider trading activity, there have been 12 purchases (100,407 shares in total) and 15 sale (103,407 shares in total) in the last 3 months. In the last 6 months, there have been 14 insider buys amounting to 120,407 shares and 17 insider sales amounting to 123,407 shares. In the past full year, 14 insider purchases were made (involving 120,407 shares) and 21 insider sell-offs equivalent to 1,754,674 shares.
Moving onto liquidity, Karyopharm Therapeutics Inc. (KPTI) has a Current Ratio of 7.13, a Quick Ratio of 7.13 and a Cash Ratio of 7.00. Looking at this company’s capital structure, its Total Debt to Total Equity is 56.05, its Total Debt to Total Capital is 35.92, and its Total Debt to Total Assets is now 30.09. Looking even further ahead into the future, its Long-Term Debt to Equity is -72.16 and its Long-Term Debt to Total Capital is 56.05.